115 related articles for article (PubMed ID: 36120775)
1. Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Wei S; Dang L; Gao F; Wang J; Wang J; Qu Q
J Alzheimers Dis; 2022; 90(1):349-362. PubMed ID: 36120775
[TBL] [Abstract][Full Text] [Related]
2. Blood Triglyceride and High-Density Lipoprotein Levels Are Associated with Plasma Amyloid-β Transport: A Population-Based Cross-Sectional Study.
Wei S; Shang S; Dang L; Gao F; Gao Y; Gao L; Chen C; Huo K; Wang J; Wang J; Qu Q
J Alzheimers Dis; 2021; 84(1):303-314. PubMed ID: 34542070
[TBL] [Abstract][Full Text] [Related]
3. Relationship Between Peripheral Transport Proteins and Plasma Amyloid-β in Patients with Alzheimer's Disease Were Different from Cognitively Normal Controls: A Propensity Score Matching Analysis.
Gao L; Wang J; Jiang Y; Wei S; Shang S; Chen C; Dang L; Huo K; Deng M; Wang J; Qu Q
J Alzheimers Dis; 2020; 78(2):699-709. PubMed ID: 33016902
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E ε4 Allele is Associated With Plasma Amyloid Beta and Amyloid Beta Transporter Levels: A Cross-sectional Study in a Rural Area of Xi'an, China.
Wei S; Gao L; Jiang Y; Shang S; Chen C; Dang L; Zhao B; Zhang J; Wang J; Huo K; Wang J; Zhang R; Qu Q
Am J Geriatr Psychiatry; 2020 Feb; 28(2):194-204. PubMed ID: 31350163
[TBL] [Abstract][Full Text] [Related]
5. The Level of Plasma Amyloid-β40 Is Correlated with Peripheral Transport Proteins in Cognitively Normal Adults: A Population-Based Cross-Sectional Study.
Gao L; Jiang Y; Wei S; Shang S; Li P; Chen C; Dang L; Wang J; Huo K; Deng M; Wang J; Zhang R; Qu Q
J Alzheimers Dis; 2018; 65(3):951-961. PubMed ID: 30103331
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.
Sano M; Bell KL; Galasko D; Galvin JE; Thomas RG; van Dyck CH; Aisen PS
Neurology; 2011 Aug; 77(6):556-63. PubMed ID: 21795660
[TBL] [Abstract][Full Text] [Related]
7. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.
Simons M; Schwärzler F; Lütjohann D; von Bergmann K; Beyreuther K; Dichgans J; Wormstall H; Hartmann T; Schulz JB
Ann Neurol; 2002 Sep; 52(3):346-50. PubMed ID: 12205648
[TBL] [Abstract][Full Text] [Related]
8. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.
Carlsson CM; Gleason CE; Hess TM; Moreland KA; Blazel HM; Koscik RL; Schreiber NT; Johnson SC; Atwood CS; Puglielli L; Hermann BP; McBride PE; Stein JH; Sager MA; Asthana S
J Alzheimers Dis; 2008 Mar; 13(2):187-97. PubMed ID: 18376061
[TBL] [Abstract][Full Text] [Related]
9. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
Bays HE; Stein EA; Shah AK; Maccubbin DL; Mitchel YB; Mercuri M
Am J Cardiol; 2002 Nov; 90(9):942-6. PubMed ID: 12398959
[TBL] [Abstract][Full Text] [Related]
10. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Riekse RG; Li G; Petrie EC; Leverenz JB; Vavrek D; Vuletic S; Albers JJ; Montine TJ; Lee VM; Lee M; Seubert P; Galasko D; Schellenberg GD; Hazzard WR; Peskind ER
J Alzheimers Dis; 2006 Dec; 10(4):399-406. PubMed ID: 17183151
[TBL] [Abstract][Full Text] [Related]
11. Sleep Deprivation Induced Plasma Amyloid-β Transport Disturbance in Healthy Young Adults.
Wei M; Zhao B; Huo K; Deng Y; Shang S; Liu J; Li Y; Ma L; Jiang Y; Dang L; Chen C; Wei S; Zhang J; Yang H; Gao F; Qu Q
J Alzheimers Dis; 2017; 57(3):899-906. PubMed ID: 28304302
[TBL] [Abstract][Full Text] [Related]
12. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
[TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
14. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
Stein E; Plotkin D; Bays H; Davidson M; Dujovne C; Korenman S; Stepanavage M; Mercuri M
Am J Cardiol; 2000 Aug; 86(4):406-11. PubMed ID: 10946033
[TBL] [Abstract][Full Text] [Related]
15. Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.
Magán-Fernández A; Papay-Ramírez L; Tomás J; Marfil-Álvarez R; Rizzo M; Bravo M; Mesa F
J Periodontol; 2014 Oct; 85(10):1408-15. PubMed ID: 24555750
[TBL] [Abstract][Full Text] [Related]
16. Statins for the treatment of dementia.
McGuinness B; O'Hare J; Craig D; Bullock R; Malouf R; Passmore P
Cochrane Database Syst Rev; 2010 Aug; (8):CD007514. PubMed ID: 20687089
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
Wang TD; Chen WJ; Lin JW; Cheng CC; Chen MF; Lee YT
Atherosclerosis; 2003 Oct; 170(2):315-23. PubMed ID: 14612213
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
20. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
